VIRAFERONPEG Side Effects

6973616-6 | Haematuria, Nephrolithiasis, Proteinuria, Renal Colic
on Aug 31, 2010 Male patient from FRANCE , weighting 165.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: haematuria, nephrolithiasis, proteinuria, renal colic. Viraferonpeg dosage: 40 Mcg; Qw; Sc. During the same period patient was treated with REBETOL (400 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), XYZAL (View Xyzal Review and Xyzal Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6900728-5 | Aspartate Aminotransferase Increased, Condition Aggravated, Gamma-glutamyltransferase Increased, Hepatitis C
Patient was taking Viraferonpeg (View Usage). Patient had the following side effects: aspartate aminotransferase increased, condition aggravated, gamma-glutamyltransferase increased, hepatitis c (What is hepatitis c?) on Jul 22, 2010 from FRANCE Additional patient health information: Male patient , 52 years of age, weighting 159.2 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 36 Mcg;qw;sc. During the same period patient was treated with REBETOL (1000 Mg;qd;po) (View Rebetol Review and Rebetol Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ).

6822166-6 | Agitation, Anuria, Colitis, Cough, Cytolytic Hepatitis, Dialysis, Disseminated Intravascular Coagulation, Lipase Increased, Metabolic Acidosis
Adverse event was reported on Jun 29, 2010 by a Female patient taking Viraferonpeg (View Usage) (Dosage: Po) was diagnosed with hepatitis c (What is hepatitis c?), hiv infection (What is hiv infection?) and. Location: FRANCE , 48 years of age, After Viraferonpeg was administered, patient had the following side effects: agitation, anuria, colitis, cough, cytolytic hepatitis, dialysis (What is dialysis?), disseminated intravascular coagulation, lipase increased, metabolic acidosis. During the same period patient was treated with REBETOL (Po) (View Rebetol Review and Rebetol Label ), VIDEX (Po) (View Videx Review and Videx Label ), NORVIR (1 Df; Qd; Po) (View Norvir Review and Norvir Label ), REYATAZ (300 Mg; Qd; Po) (View Reyataz Review and Reyataz Label ), VIREAD (1 Df; Qd; Po) (View Viread Review and Viread Label ), BACTRIM (View Bactrim Review and Bactrim Label ). Patient was hospitalized.

6817038-7 |
on Jun 25, 2010 Male patient from FRANCE , 20 years of age, weighting 169.8 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). . Viraferonpeg dosage: . During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ).


6800354-2 | Tinnitus
on Jun 16, 2010 Male patient from IRELAND , 50 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: tinnitus (What is tinnitus?). Viraferonpeg dosage: 120 Mg; Qw; Sc. During the same period patient was treated with REBETOL (1000 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ).

6800050-1 | Cholelithiasis, Multi-organ Failure
Patient was taking Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: cholelithiasis, multi-organ failure on Jun 14, 2010 from INDIA Additional patient health information: Female patient , 65 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 80 Mcg;. During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6753823-8 | Cholelithiasis, Multi-organ Failure
Adverse event was reported on May 25, 2010 by a Female patient taking Viraferonpeg (View Usage) (Dosage: 80 Mcg) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: INDIA , 65 years of age, Patient experienced the following unwanted or unexpected effects: cholelithiasis, multi-organ failure. During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6751081-1 | Decreased Appetite, Latent Tuberculosis, Pulmonary Tuberculosis
on May 18, 2010 Male patient from FRANCE , weighting 154.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: decreased appetite, latent tuberculosis, pulmonary tuberculosis. Viraferonpeg dosage: 0.45 Ml; Qw; Sc. During the same period patient was treated with REBETOL (1000 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6729752-2 | Asthenia, Hepatic Cyst, Prothrombin Level Decreased, Pulmonary Embolism
on May 07, 2010 Female patient from FRANCE , 65 years of age, weighting 163.1 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: asthenia, hepatic cyst, prothrombin level decreased, pulmonary embolism (What is pulmonary embolism?). Viraferonpeg dosage: 45 Mcg;qw;sc, 40 Mcg;qw, 35 Msc;qw, 30 Mcg;qw. During the same period patient was treated with REBETOL (1200 Mg;qd;po, 1000 Mg;qd;po, 600 Mg;qd;po, 400 Mg;qd;po) (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6720253-4 | Asthenia, Myocarditis
Patient was taking Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, myocarditis on Apr 28, 2010 from FRANCE Additional patient health information: Female patient , 49 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 110 Mcg;qw;. During the same period patient was treated with RIBAVIRIN (1000 Mg;qd;po) (View Ribavirin Review and Ribavirin Label ), TAHOR (CON.) (View Tahor (con.) Review and Tahor (con.) Label ). Patient was hospitalized.

6670334-9 | Condition Aggravated, Dehydration, Hepatitis C, Suicidal Ideation, Transaminases Increased
Adverse event was reported on Mar 26, 2010 by a Female patient taking Viraferonpeg (View Usage) (Dosage: ; Sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: FRANCE , 67 years of age, Patient had the following side effects: condition aggravated, dehydration, hepatitis c (What is hepatitis c?), suicidal ideation, transaminases increased. During the same period patient was treated with REBETOL (; Po) (View Rebetol Review and Rebetol Label ).

6643804-7 | Asthenia, Chest Pain, Myocarditis, Vomiting
on Mar 09, 2010 Female patient from FRANCE , 49 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: asthenia, chest pain (What is chest pain?), myocarditis, vomiting. Viraferonpeg dosage: 110 Mcg;qw. During the same period patient was treated with RIBAVIRIN (1000 Mg;qd;po) (View Ribavirin Review and Ribavirin Label ), TAHOR (View Tahor Review and Tahor Label ). Patient was hospitalized.

6555800-9 | Femoral Neck Fracture, Malaise, Road Traffic Accident
on Jan 15, 2010 Male patient from FRANCE , 43 years of age, weighting 125.7 lb, was diagnosed with hepatitis c (What is hepatitis c?), anaemia, hypertension, sleep disorder (What is sleep disorder?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: femoral neck fracture, malaise, road traffic accident. Viraferonpeg dosage: 100 Mcg; Qw; Sc. During the same period patient was treated with REBETOL (1000 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), NEURECORMON (EPOETIN BETA) (300000 Iu; Qw; Sc) (View Neurecormon (epoetin Beta) Review and Neurecormon (epoetin Beta) Label ), NIFEDIPINE (20 Mg; Qd; Po) (View Nifedipine Review and Nifedipine Label ), XANAX (0.5 Mg; Qd; Po) (View Xanax Review and Xanax Label ). Patient was hospitalized.

6517713-8 | Ascites, Nephrotic Syndrome
Patient was taking Viraferonpeg (View Usage). Patient had the following side effects: ascites, nephrotic syndrome on Dec 16, 2009 from FRANCE Additional patient health information: Male patient , 35 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 120 Mg; Qw; Sc. During the same period patient was treated with REBETOL (200 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LEXOMIL (View Lexomil Review and Lexomil Label ). Patient was hospitalized.

6491917-5 | Acute Coronary Syndrome, Arteriospasm Coronary, Chest Pain, Electrocardiogram St Segment Elevation, Electrocardiogram T Wave Inversion, Troponin Increased
Adverse event was reported on Dec 07, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 120 Mcg;qw;sc) . Location: FRANCE , 41 years of age, After Viraferonpeg was administered, patient had the following side effects: acute coronary syndrome, arteriospasm coronary, chest pain (What is chest pain?), electrocardiogram st segment elevation, electrocardiogram t wave inversion, troponin increased. During the same period patient was treated with REBETOL (1000 Mg;qd;po) (View Rebetol Review and Rebetol Label ), SUBUTEX (View Subutex Review and Subutex Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), ADVIL (View Advil Review and Advil Label ). Patient was hospitalized.

6472494-1 | Ketoacidosis, Type 1 Diabetes Mellitus
on Nov 20, 2009 Male patient from FRANCE , 35 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: ketoacidosis, type 1 diabetes mellitus. Viraferonpeg dosage: 80 Mcg;qw;sc. During the same period patient was treated with RIBAVIRIN (800 Mg;qd;po) (View Ribavirin Review and Ribavirin Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ). Patient was hospitalized.

6463560-5 | Cardiac Failure, Cardiomyopathy, Dyspnoea, Fatigue, Haemodynamic Instability, Pleural Effusion, Tachycardia
on Nov 18, 2009 Male patient from FRANCE , 50 years of age, was diagnosed with hepatitis c positive and was treated with Viraferonpeg (View Usage). Patient had the following side effects: cardiac failure, cardiomyopathy (What is cardiomyopathy?), dyspnoea, fatigue, haemodynamic instability, pleural effusion, tachycardia. Viraferonpeg dosage: 1.5 Mcg/kg;qw;sc. During the same period patient was treated with COPEGUS (Po) (View Copegus Review and Copegus Label ), PROGRAF (8.5 Mg;bid; Po) (View Prograf Review and Prograf Label ). Patient was hospitalized.

6428312-0 | Aspiration, Cardiovascular Disorder, Haemoglobin Decreased, Obstruction, Pancreatic Pseudocyst, Platelet Count Decreased, Renal Failure, Sepsis
Patient was taking Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: aspiration, cardiovascular disorder, haemoglobin decreased, obstruction, pancreatic pseudocyst, platelet count decreased, renal failure, sepsis (What is sepsis?) on Oct 29, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 45 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 100 Mcg; Qw;. During the same period patient was treated with REBETOL (1000 Mg; Qd;) (View Rebetol Review and Rebetol Label ).

6413584-9 | Bile Duct Stone, Delusion, Hallucination
Adverse event was reported on Oct 12, 2009 by a Female patient taking Viraferonpeg (View Usage) (Dosage: 90 Mcg; Qw; Sc) . Location: FRANCE , 52 years of age, Patient experienced the following unwanted or unexpected effects: bile duct stone, delusion, hallucination. During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ), CIPROFLOXACIN HCL (400 Mg; Iv; 1000 Mg) (View Ciprofloxacin Hcl Review and Ciprofloxacin Hcl Label ), FLAGYL (View Flagyl Review and Flagyl Label ), TAZOCILLINE (View Tazocilline Review and Tazocilline Label ), CELLCEPT (View Cellcept Review and Cellcept Label ), NEORAL (View Neoral Review and Neoral Label ), EFFEXOR (View Effexor Review and Effexor Label ). Patient was hospitalized.

6407571-4 | Anaemia, Arteriospasm Coronary, Coronary Artery Stenosis
on Oct 13, 2009 Male patient from FRANCE , 48 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: anaemia, arteriospasm coronary, coronary artery stenosis. Viraferonpeg dosage: 108 Mcg;sc. During the same period patient was treated with REBETOL (1400 Mg;qd;po) (View Rebetol Review and Rebetol Label ), PARACETAMOL (CON.) (View Paracetamol (con.) Review and Paracetamol (con.) Label ). Patient was hospitalized.

6407561-1 | Anaemia, Anxiety, Arterial Stenosis, Cardiac Stress Test Abnormal, Chest Pain
on Oct 13, 2009 Male patient from FRANCE , 48 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: anaemia, anxiety (What is anxiety?), arterial stenosis, cardiac stress test abnormal, chest pain (What is chest pain?). Viraferonpeg dosage: 108 Mcg; Sc. During the same period patient was treated with REBETOL (1400 Mg;qd;po) (View Rebetol Review and Rebetol Label ), PARACETAMOL (CON.) (View Paracetamol (con.) Review and Paracetamol (con.) Label ). Patient was hospitalized.

6384483-6 | Hypopituitarism
Patient was taking Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: hypopituitarism on Sep 25, 2009 from FRANCE Additional patient health information: Male patient , 65 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 1.5 Mcg/kg; Qw. During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6380399-X |
Adverse event was reported on Sep 20, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 80 Mcg; Qd; Sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: INDIA , 45 years of age, . During the same period patient was treated with RIBAVIRIN (1000 Mg; Qd; Po) (View Ribavirin Review and Ribavirin Label ).

6380398-8 | Angina Pectoris, Coronary Artery Stenosis, Haemoglobin Decreased
on Sep 17, 2009 Male patient from FRANCE , 48 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: angina pectoris, coronary artery stenosis, haemoglobin decreased. Viraferonpeg dosage: . During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ).

6337156-X | Dysarthria, Dyspnoea, Haemoglobin Decreased
on Aug 27, 2009 Female patient from FRANCE , 64 years of age, weighting 163.1 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: dysarthria, dyspnoea, haemoglobin decreased. Viraferonpeg dosage: 120 Mcg; Qw; Sc. During the same period patient was treated with REBETOL (1000 Mg; Qd; Po, 600 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6249916-4 | Blood Glucose Increased, Fall, Haemorrhagic Stroke, Hemiplegia
Patient was taking Viraferonpeg (View Usage). Patient had the following side effects: blood glucose increased, fall (What is fall?), haemorrhagic stroke, hemiplegia on Jun 23, 2009 from FRANCE Additional patient health information: Male patient , 79 years of age, weighting 132.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 0.5 Mcg/kg;qw;. During the same period patient was treated with RIBAVIRIN (800 Mg/qd) (View Ribavirin Review and Ribavirin Label ), STAGID (CON.) (View Stagid (con.) Review and Stagid (con.) Label ), DIAMICRON (CON.) (View Diamicron (con.) Review and Diamicron (con.) Label ), GLUCOR 50 (CON.) (View Glucor 50 (con.) Review and Glucor 50 (con.) Label ). Patient was hospitalized.

6239284-6 | Pericarditis
Adverse event was reported on Jun 10, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 0.45 Ml;qw;sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: FRANCE , 46 years of age, weighting 205.0 lb, After Viraferonpeg was administered, patient had the following side effects: pericarditis. During the same period patient was treated with REBETOL (1000 Mg;qd;po) (View Rebetol Review and Rebetol Label ).

6235339-0 | Dyspnoea, Haemoglobin Decreased, Speech Disorder
on Jun 09, 2009 Female patient from FRANCE , 64 years of age, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, haemoglobin decreased, speech disorder. Viraferonpeg dosage: Sc. During the same period patient was treated with REBETOL (Po; 600 Mg;qd; Po) (View Rebetol Review and Rebetol Label ). Patient was hospitalized.

6223202-0 | Cerebellar Syndrome, Confusional State, Neurological Symptom, Therapeutic Agent Toxicity
on Jun 03, 2009 Male patient from FRANCE , 69 years of age, was diagnosed with hepatitis c (What is hepatitis c?), bipolar disorder (What is bipolar disorder?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: cerebellar syndrome, confusional state, neurological symptom, therapeutic agent toxicity. Viraferonpeg dosage: ; Sc. During the same period patient was treated with REBETOL (1200 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), LITHIUM CARBONATE (1250 Mg; Qd; Po) (View Lithium Carbonate Review and Lithium Carbonate Label ), DEPAMIDE (View Depamide Review and Depamide Label ). Patient was hospitalized.

6209733-8 | Nephrolithiasis, Renal Colic
Patient was taking Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: nephrolithiasis, renal colic on May 20, 2009 from FRANCE Additional patient health information: Male patient , 54 years of age, weighting 165.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 0.5 Mcg; Qw; Sc. During the same period patient was treated with REBETOL (400 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), XYZAL (View Xyzal Review and Xyzal Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ). Patient was hospitalized.

6183127-6 | Agitation, Ascites, Confusional State, Disease Progression, Gastrointestinal Haemorrhage, Gynaecomastia, Hepatic Cirrhosis, Hepatic Encephalopathy, Hepatic Fibrosis
Adverse event was reported on May 04, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 45 Mcg/kg;qw;sc) was diagnosed with hepatitis c (What is hepatitis c?), insomnia and. Location: FRANCE , 64 years of age, weighting 178.6 lb, Patient experienced the following unwanted or unexpected effects: agitation, ascites, confusional state, disease progression, gastrointestinal haemorrhage, gynaecomastia, hepatic cirrhosis, hepatic encephalopathy, hepatic fibrosis. During the same period patient was treated with XANAX (0.25 Mg;qd;po) (View Xanax Review and Xanax Label ). Patient was hospitalized.

6183126-4 | Agitation, Aortic Calcification, Colonic Polyp, Rectal Haemorrhage, Synovial Cyst
on Apr 30, 2009 Male patient from FRANCE , 49 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: agitation, aortic calcification, colonic polyp (What is colonic polyp?), rectal haemorrhage, synovial cyst. Viraferonpeg dosage: 39 Mcg/kg; Qw; Sc. During the same period patient was treated with REBETOL (1000 Mg;qd;po) (View Rebetol Review and Rebetol Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), TRANXENE (View Tranxene Review and Tranxene Label ), SERESTA (View Seresta Review and Seresta Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), LOVENOX (View Lovenox Review and Lovenox Label ).

6178635-8 | Agitation, Aortic Calcification, Catheter Related Complication, Intestinal Polyp, Rectal Haemorrhage
on Apr 27, 2009 Male patient from FRANCE , 49 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: agitation, aortic calcification, catheter related complication, intestinal polyp, rectal haemorrhage. Viraferonpeg dosage: 0.5 Mcg/kg;qw;sc. During the same period patient was treated with RIBAVIRIN (1000 Mg;qd;po) (View Ribavirin Review and Ribavirin Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), TRANXENE (View Tranxene Review and Tranxene Label ), SERESTA (View Seresta Review and Seresta Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), LOVENOX (View Lovenox Review and Lovenox Label ).

6173041-4 | Agitation, Rectal Haemorrhage, Vascular Calcification
Patient was taking Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, rectal haemorrhage, vascular calcification on Apr 23, 2009 from FRANCE Additional patient health information: Male patient , 49 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 0.5 Mcg/kg; Qw;sc. During the same period patient was treated with DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), TRANXENE (View Tranxene Review and Tranxene Label ), SERESTA (View Seresta Review and Seresta Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), LOVENOX (View Lovenox Review and Lovenox Label ).

6160502-7 | Accidental Needle Stick, Device Failure
Adverse event was reported on Apr 09, 2009 by a Female patient taking Viraferonpeg (View Usage) (Dosage: ) . Location: , 29 years of age, Patient had the following side effects: accidental needle stick, device failure.

6153655-8 | Haematuria, Lymphadenopathy, Nephrolithiasis, Proteinuria, Renal Colic
on Apr 02, 2009 Male patient from FRANCE , 54 years of age, weighting 165.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: haematuria, lymphadenopathy, nephrolithiasis, proteinuria, renal colic. Viraferonpeg dosage: 0.5 Mcg; Qw; Sc. During the same period patient was treated with REBETOL (400 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), XYZAL (View Xyzal Review and Xyzal Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ). Patient was hospitalized.

6151294-6 |
on Apr 02, 2009 Male patient from FRANCE , 49 years of age, weighting 149.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). . Viraferonpeg dosage: 0.5 Mcg/kg; Qw; Sc. During the same period patient was treated with DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), TRANXENE (View Tranxene Review and Tranxene Label ), SERESTA (View Seresta Review and Seresta Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), LOVENOX (View Lovenox Review and Lovenox Label ).

6148418-3 | Haematuria, Lymphadenopathy, Proteinuria, Renal Colic
Patient was taking Viraferonpeg (View Usage). Patient had the following side effects: haematuria, lymphadenopathy, proteinuria, renal colic on Mar 31, 2009 from FRANCE Additional patient health information: Male patient , 54 years of age, weighting 165.3 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 0.5 Mcg;qw;sc. During the same period patient was treated with REBETOL (1000 Mg;qd;po) (View Rebetol Review and Rebetol Label ), XYZAL (View Xyzal Review and Xyzal Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ). Patient was hospitalized.

6146049-2 |
Adverse event was reported on Mar 30, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 0.5 Mcg/kg; Qw; Sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: FRANCE , 49 years of age, weighting 149.9 lb, . During the same period patient was treated with DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), TRANXENE (View Tranxene Review and Tranxene Label ), SERESTA (View Seresta Review and Seresta Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), LOVENOX (View Lovenox Review and Lovenox Label ).

6140296-1 | Agitation, Disease Progression, Gastrointestinal Haemorrhage, Hepatic Cirrhosis, Hepatic Encephalopathy, Hyponatraemia, Insomnia, Portal Hypertension, Respiratory Disorder
on Mar 25, 2009 Male patient from FRANCE , 64 years of age, weighting 178.6 lb, was diagnosed with hepatitis c (What is hepatitis c?), insomnia and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, disease progression, gastrointestinal haemorrhage, hepatic cirrhosis, hepatic encephalopathy, hyponatraemia, insomnia, portal hypertension, respiratory disorder. Viraferonpeg dosage: 45 Mcg; Qw; Sc. During the same period patient was treated with XANAX (0.25 Mg; Qd; Po) (View Xanax Review and Xanax Label ). Patient was hospitalized.

6133565-2 | Amnesia, Anxiety, Convulsion, Depressed Level Of Consciousness, Derealisation, Fatigue, Feeling Hot, Femoral Neck Fracture
on Mar 16, 2009 Male patient from FRANCE , 43 years of age, was diagnosed with hepatitis c (What is hepatitis c?), anxiety (What is anxiety?), pain (What is pain?) and was treated with Viraferonpeg (View Usage). Patient had the following side effects: amnesia, anxiety (What is anxiety?), convulsion, depressed level of consciousness, derealisation, fatigue, feeling hot, femoral neck fracture. Viraferonpeg dosage: 100 Mcg;qw;sc; 0 Mcg;. During the same period patient was treated with REBETOL (1000 Mg;qd;po; Po) (View Rebetol Review and Rebetol Label ), XANAX (1 Mg;qd; Po) (View Xanax Review and Xanax Label ), STRESAM (ETIFOXINE) (2 Df; Qd; Po) (View Stresam (etifoxine) Review and Stresam (etifoxine) Label ), EFFERALGAN CODEINE (PANADELINE CO) (1 Df; Qd; Po) (View Efferalgan Codeine (panadeline Co) Review and Efferalgan Codeine (panadeline Co) Label ), ADALAT (View Adalat Review and Adalat Label ). Patient was hospitalized.

6125216-8 | Aspartate Aminotransferase Increased
Patient was taking Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: aspartate aminotransferase increased on Mar 06, 2009 from FRANCE Additional patient health information: Female patient , 68 years of age, weighting 112.4 lb, was diagnosed with hepatitis c (What is hepatitis c?), peripheral coldness and. Viraferonpeg dosage: 25.5 Mcg; Qw; Sc. During the same period patient was treated with NAFTIDROFURYL (NAFTIDROFURYL) (200 Mg;tid) (View Naftidrofuryl (naftidrofuryl) Review and Naftidrofuryl (naftidrofuryl) Label ).

6121306-4 | Choroiditis, Intraocular Pressure Increased
Adverse event was reported on Mar 06, 2009 by a Male patient taking Viraferonpeg (View Usage) (Dosage: 108 Mcg; Qw; Sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: FRANCE , 33 years of age, weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: choroiditis, intraocular pressure increased. During the same period patient was treated with REBETOL (1000 Mg; Qd; Po) (View Rebetol Review and Rebetol Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ). Patient was hospitalized.

6111174-9 | Aspartate Aminotransferase Increased
on Mar 04, 2009 Female patient from FRANCE , 68 years of age, weighting 112.4 lb, was diagnosed with hepatitis c (What is hepatitis c?), feeling cold and was treated with Viraferonpeg (View Usage). Patient had the following side effects: aspartate aminotransferase increased. Viraferonpeg dosage: 0.5 Mcg/kg;qw;sc. During the same period patient was treated with NAFTIDROFURYL (NAFTIDROFURYL) (200 Mg; Tid) (View Naftidrofuryl (naftidrofuryl) Review and Naftidrofuryl (naftidrofuryl) Label ), COTRIATEC (View Cotriatec Review and Cotriatec Label ), HEPTAMYL (View Heptamyl Review and Heptamyl Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), LYSANXIA (View Lysanxia Review and Lysanxia Label ).

6103666-3 | Candidiasis, Cheilitis, Dry Mouth, Oral Mucosal Erythema, Salivary Gland Disorder, Tongue Disorder
on Feb 18, 2009 Female patient from UNITED KINGDOM , 63 years of age, was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: candidiasis, cheilitis, dry mouth, oral mucosal erythema, salivary gland disorder (What is salivary gland disorder?), tongue disorder. Viraferonpeg dosage: . During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ), MIRTAZAPINE (View Mirtazapine Review and Mirtazapine Label ).

6075730-9 | Fatigue, Haemoglobin Decreased, Paralysis, Rhabdomyolysis, Speech Disorder, Vomiting
Patient was taking Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: fatigue, haemoglobin decreased, paralysis (What is paralysis?), rhabdomyolysis, speech disorder, vomiting on Jan 28, 2009 from FRANCE Additional patient health information: Female patient , 74 years of age, weighting 160.9 lb, was diagnosed with hepatitis c (What is hepatitis c?) and. Viraferonpeg dosage: 108 Mcg;qw;. During the same period patient was treated with REBETOL (1000 Mg;) (View Rebetol Review and Rebetol Label ), PLAVIX (View Plavix Review and Plavix Label ). Patient was hospitalized.

6059457-5 | Aspartate Aminotransferase Increased
Adverse event was reported on Jan 23, 2009 by a Female patient taking Viraferonpeg (View Usage) (Dosage: 0.5 Mcg/kg;qs;sc) was diagnosed with hepatitis c (What is hepatitis c?) and. Location: FRANCE , 68 years of age, weighting 112.4 lb, Patient had the following side effects: aspartate aminotransferase increased. During the same period patient was treated with COTRIATEC (View Cotriatec Review and Cotriatec Label ), HEPTAMYL (View Heptamyl Review and Heptamyl Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), NAFTIDROFURYL (View Naftidrofuryl Review and Naftidrofuryl Label ), PRAZEPAM (View Prazepam Review and Prazepam Label ).

6058131-9 | Sjogren's Syndrome
on Jan 16, 2009 Female patient from UNITED KINGDOM , 63 years of age, was treated with Viraferonpeg (View Usage). After Viraferonpeg was administered, patient had the following side effects: sjogren's syndrome (What is sjogren's syndrome?). Viraferonpeg dosage: . During the same period patient was treated with REBETOL (View Rebetol Review and Rebetol Label ).

6058126-5 | Acute Myeloid Leukaemia Recurrent, Anaemia Macrocytic, Autoimmune Disorder, Bronchitis, Erythema Multiforme, Pancytopenia, Urticaria
on Jan 23, 2009 Female patient from FRANCE , 60 years of age, weighting 196.2 lb, was diagnosed with hepatitis c (What is hepatitis c?) and was treated with Viraferonpeg (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia recurrent, anaemia macrocytic, autoimmune disorder, bronchitis (What is bronchitis?), erythema multiforme, pancytopenia, urticaria. Viraferonpeg dosage: 1.5 Mcg/kg;qw;sc;0.5 Mcg/kg;qw. During the same period patient was treated with COVERSYL (View Coversyl Review and Coversyl Label ), LEVOTHYROX (View Levothyrox Review and Levothyrox Label ), ORELOX (View Orelox Review and Orelox Label ), SPECIAFOLDINE (View Speciafoldine Review and Speciafoldine Label ).

6054971-0 | Cytolytic Hepatitis, Hepatitis Toxic, Influenza Like Illness, Lymphopenia, Neutropenia, Thrombocytopenia
Patient was taking Viraferonpeg (View Usage). Patient had the following side effects: cytolytic hepatitis, hepatitis toxic, influenza like illness, lymphopenia, neutropenia, thrombocytopenia on Jan 14, 2009 from FRANCE Additional patient health information: Female patient , 33 years of age, was diagnosed with malignant melanoma and. Viraferonpeg dosage: 350 Mcg;qw; Sc. During the same period patient was treated with STABLON (View Stablon Review and Stablon Label ), XANAX (View Xanax Review and Xanax Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), IBUPROFENE (View Ibuprofene Review and Ibuprofene Label ), VOGALENE (View Vogalene Review and Vogalene Label ). Patient was hospitalized.